Compassionate Use of Deferiprone in Patients With PKAN

Summary

Patients with pantothenate kinase-associated neurodegeneration (PKAN) who have completed the ApoPharma-sponsored study TIRCON2012V1-EXT and who wish to continue to take deferiprone will be offered the opportunity to receive it on a compassionate basis. Patients will be followed locally by their own neurologist or other appropriate specialist.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications